Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil

Brazilian Journal of Infectious Diseases

Volumn 18, Issue 4, 2014, Pages 379-386

  Tauil, Márcia de Cantuária ^a   de Carvalho, Cleidiane Santos Rodrigues ^b   Vieira, Ataiza César ^c   Waldman, Eliseu Alves ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Secretaria de Estado de Saude do Distrito Federal   (Brazil)

^c Laboratório Central de Saúde Pública do Distrito Federal LACEN DF   (Brazil)

Author keywords

Control; Epidemiology; Meningococcal disease

Indexed keywords

MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BRAZIL; CHILD; CLINICAL EFFECTIVENESS; DESCRIPTIVE RESEARCH; DISEASE ACTIVITY; DISEASE SURVEILLANCE; FATALITY; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORTALITY; OUTCOME ASSESSMENT; PHENOTYPE; RISK REDUCTION; CASE FATALITY; DRUG EFFECT; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH IMPACT ASSESSMENT; INFANT; INFECTION CONTROL; MASS IMMUNIZATION; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME;

CONTROL; EPIDEMIOLOGY; MENINGOCOCCAL DISEASE;

ADOLESCENT; ADULT; AGED; BRAZIL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; PHENOTYPE; POPULATION SURVEILLANCE; PROGRAM EVALUATION; YOUNG ADULT;

EID: 84904036124     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.11.012     Document Type: Article

References (34)

1. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
2. Morais J.S., Munford R.S., Risi J.B., Antezana E., Feldman R.A. Epidemic disease due to serogroup C Neisseria meningitidis in São Paulo, Brazil. J Infect Dis 1974, 129:568-571.
3. Baethgen L.F., Weidlich L., Moraes C., et al. Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing. Trop Med Int Health 2008, 13:31-40.
4. Lemos A.P.S., Yara T.Y., Gorla M.C.O., et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in Greater São Paulo, Brazil. J Clin Microbiol 2007, 45:1266-1273.
5. Azevedo L.C.P., Toscano C.M., Bierrenbach A.L. Bacterial meningitis in Brazil: baseline epidemiologic assessment of the decade prior to the introduction of pneumococcal and meningococcal vaccines. PLoS ONE 2013, 8:e64524.
6. Brasil. Ministério da Saúde Nota técnica. Doença meningocócica no Brasil. 2009.
7. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002, 51:717-722.
8. Booy R., Jelfs J., Bashir H., Nissen M.D. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 2007, 186:108.
9. Brasil Fundação Instituto Brasileiro de Geografia e Estatística - IBGE. [accessed 08.02.12]. http://www.ibge.gov.br/estadosat/perfil.php%3Fsigla=df.
10. Governo do Distrito Federal - GDF. [accessed 08.02.12]. http://www.gdf.df.gov.br/045/04501018.asp.
11. Programa das Nações Unidas para o Desenvolvimento - PNUD. [accessed 08.02.12]. http://www.pnud.org.br/.
12. Governo do Distrito Federal - GDF Indicadores de Desigualdade Social no Distrito Federal/Companhia de Planejamento do Distrito Federal 2007, CODEPLAN: NEP, Brasília, DF, [accessed 08.02.12]. http://www.codeplan.df.gov.br/.
13. Organização Mundial da Saúde - OMS CID-10 Classificação Estatística Internacional de Doenças e Problemas Relacionados à Saúde 2009, vol. 3. Universidade de São Paulo, São Paulo. 10a rev.
14. Moraes J.C., Barata R.B. A doença meningocócica em São Paulo. Brasil, no século XX: características epidemiológicas. Cad Saúde Pública 2005, 21:1458-1471.
15. Sáfadi M.A.P., Cintra O.A.L. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010, 32:263-271.
16. Santos M.L., Ruffino-Netto A. Doença meningocócica: situação epidemiológica no Município de Manaus, Amazonas, Brasil, 1998/2002. Cad Saúde Pública 2005, 21:823-829.
17. Stein-Zamir C., Abramson N., Zentner G., Shoob H., Valinsky L., Block C. Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect 2008, 136:782-789.
18. Boulton R.B., Alder S.C., Mottice S., Catinella A., Byington C.L. Invasive meningococcal disease, Utah, 1995-2005. Emerg Infect Dis 2007, 13:1225-1227.
19. Ministério da Saúde Brasil. [accessed 07.02.13]. http://www2.datasus.gov.br/DATASUS/index.php%3Farea=02.
20. Masuda E.T. Doença meningocócica: indicadores de gravidade e sua importância para a vigilância e assistência médico hospitalar 2009, [Dissertação de mestrado], Faculdade de Saúde Pública da USP, São Paulo.
21. Donalisio M.R.C., Kemp B., Rocha M.M.M., Ramalheira R.M.F. Letalidade na epidemiologia da doença meningocócica: estudo na região de campinas, SP, 1993-1998. Rev de Saúde Pública 2000, 34:589-595.
22. Booy R., Habibi P., Nadel S., et al. The Meningococcal Research Group. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001, 85:386-390.
23. Duarte M.C.M.B., Amorim M.R., Cuevas L.E., Cabral-Filho J.E., Correia J.B. Risk factors for death from meningococcal infection in Recife, Brazil. J Trop Pediatr 2005, 51:227-231.
24. Mattos M.V.L., Zanetta D.M.T. A doença meningocócica na região de Sorocaba, São Paulo, Brasil, no período de 1999 a 2008. Cad Saúde Pública 2012, 28:2397-2401.
25. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl 2):B51-B63.
26. Barroso D.E., Rebelo M.C. Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil. Mem Inst Oswaldo Cruz 2007, 102:773-775.
27. Weidlich L., Baethgen L.F., Mayer L.W., et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. J Infect 2008, 57:324-331.
28. Gottberg A., Plessis M., Cohen C., et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46:377-386.
29. Ministerio de Salud Chile. [accessed 18.02.13]. http://epi.minsal.cl/presentacion-situacion-epidemiologica-w135/.
30. Larrauri A., Cano R., García M., Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
31. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
32. Sáfadi M.A.P., Berezin E.N., Oselka G.W. A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines. J Pediatr 2012, 88:195-202.
33. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
34. Khatami A., Pollard A.J. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010, 9:285-298.